MiNK Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.6%projected annual EPS growth
Analyst Coverage
2analysts covering
FY Revenue (est.)
$3.4Mnext fiscal year
FY EPS (est.)
-$1.93next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly9.5MTarget: Sufficient to fund operations for at least 12 months
Quarterly Net Loss Quarterly-2.7MTarget: Stabilized or reduced cash burn
Total Patients Treated with agenT-797 Annually54.0Target: Expansion through ongoing Phase 2 trials
Watch Items
- Efficacy and safety data readout from the ongoing randomized Phase 2 trial of agenT-797 in acute lung injury and critical illness (ARDS)Trigger: Initial efficacy data release expected in the second half of 2026Action: Evaluate clinical proof-of-concept and determine path to pivotal development
- Cash runway and going concern statusTrigger: Cash runway dropping under 12 monthsAction: Execute additional capital raises via the at-the-market (ATM) sales agreement or secure strategic non-dilutive collaborations
- IND-enabling studies progress for engineered CAR-iNKT program MiNK-215Trigger: Filing of IND application for MiNK-215Action: Transition program from preclinical to active Phase 1 clinical development
Research as of 19 Jun 2026